NMDA Enhancement Combined With Omega-3 for Early Dementia

Starting soon · Phase 2 · Has a placebo group

Conditions studied: Omega 3 Fatty Acids, Dementia

In brief

In this 4-year proposed project, we will enroll 140 patients with aMCI or mild AD into a 24-week randomized, double-blind, placebo-controlled drug trial. All patients will be allocated randomly to one of two treatment groups for 24 weeks (n = 70 in each group) in a double-blind manner: \[1\] DAOIB + omega-3; \[2\] DAOIB + placebo. We will assess the patients every 8 weeks during the treatment period (weeks 0, 8, 16, and 24). We hypothesize that DAOIB combined with omega-3 will yield better efficacy than placebo in improving the cognitive function, global functioning and quality of life in patients with aMCI or mild AD.

Key facts

Study ID

NCT05181189

Run by

Chang Gung Memorial Hospital

People needed

140

Starts

2026-08-01

Expected to finish

2028-03-01

Last updated by the study team

2026-03-20

Who can join

Age: 50 and older, up to 100. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of Alzheimer's disease or mild cognitive impairment
• MMSE between 10-26
• CDR 1 or 0.5

You may not qualify if…

• Hachinski Ischemic Score > 4
• Substance abuse/dependence
• Parkinson disease, epilepsy, dementia with psychotic features
• Major depressive disorder
• Major physical illnesses
• memantine or special omega-3 fatty acids therapy within 3 months before enrollment
• Severe visual or hearing impairment

Where it is running

• Kaohsiung Chang Gung Memorial Hospital — Kaohsiung City, Taiwan

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.